We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 131% below its sector, cheaper than its peers on earnings.
Founded in 2002 and headquartered in New Taipei, Taiwan, Lukas Biomedical Inc. primarily develops immune cell medical technologies. These innovations are utilized for regenerative medicine and as complementary treatments for cancer. The company's operations are segmented into four distinct areas: E-commerce, Medical Management Business, Cell Product, and Pharmaceutical Market. Furthermore, it diversifies its business by wholesaling and retailing cosmetics, alongside providing housing equipment rental services.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6814.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
